The raging COVID-19 pandemic is in its third year of global impact. The SARS CoV 2 virus has a high rate of spread, protean manifestations, and a high morbidity and mortality in individuals with predisposing risk factors. The pathophysiologic mechanisms involve a heightened systemic inflammatory state, cardiometabolic derangements, and varying degrees of glucose intolerance. The latter can be evident as significant hyperglycemia leading to new -onset diabetes or worsening of preexisting disease. Unfortunately, the clinical course beyond the acute phase of the illness may persist in the form of a variety of symptoms that together form the so-called "Long COVID" or "Post-COVID Syndrome". It is thought that a chronic, low-grade inflammatory and immunologic state persists during this phase, which may last for weeks or months. Although numerous insights have been gained into COVID-related hyperglycemia and diabetes, its prediction, course, and management remain to be fully elucidated.

Rizvi, A.A., Kathuria, A., Al Mahmeed, W., Al-Rasadi, K., Al-Alawi, K., Banach, M., et al. (2022). Post-COVID syndrome, inflammation, and diabetes. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 36(11), 108336 [10.1016/j.jdiacomp.2022.108336].

Post-COVID syndrome, inflammation, and diabetes

Galia, Massimo;Rizzo, Manfredi
2022-11-01

Abstract

The raging COVID-19 pandemic is in its third year of global impact. The SARS CoV 2 virus has a high rate of spread, protean manifestations, and a high morbidity and mortality in individuals with predisposing risk factors. The pathophysiologic mechanisms involve a heightened systemic inflammatory state, cardiometabolic derangements, and varying degrees of glucose intolerance. The latter can be evident as significant hyperglycemia leading to new -onset diabetes or worsening of preexisting disease. Unfortunately, the clinical course beyond the acute phase of the illness may persist in the form of a variety of symptoms that together form the so-called "Long COVID" or "Post-COVID Syndrome". It is thought that a chronic, low-grade inflammatory and immunologic state persists during this phase, which may last for weeks or months. Although numerous insights have been gained into COVID-related hyperglycemia and diabetes, its prediction, course, and management remain to be fully elucidated.
nov-2022
Rizvi, A.A., Kathuria, A., Al Mahmeed, W., Al-Rasadi, K., Al-Alawi, K., Banach, M., et al. (2022). Post-COVID syndrome, inflammation, and diabetes. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 36(11), 108336 [10.1016/j.jdiacomp.2022.108336].
File in questo prodotto:
File Dimensione Formato  
2022 JDC.pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 1.01 MB
Formato Adobe PDF
1.01 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/584543
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 26
social impact